FDA Pauses Spirulina's Glow-Up as Food Coloring Option
Published Date: 3/24/2026
Rule
Summary
The FDA is hitting the pause button on the new rules about using spirulina extract as a food color. This delay affects food makers who were ready to use spirulina more widely but now have to wait because some folks asked for a review. No safety worries yet, but the new rules won’t kick in until the FDA sorts things out, so no changes or costs happen just yet.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Spirulina color use delayed indefinitely
The FDA delayed the effective date of its February 6, 2026 final order that would have allowed expanded use of spirulina (Arthrospira platensis) extract as a color additive in human foods generally (except infant formula, certain USDA-regulated foods, and foods with standards of identity). As of March 20, 2026 the rule is delayed indefinitely and will not take effect until the FDA announces a new effective date.
New heavy-metal specs also put on hold
The FDA's February 6, 2026 order would have lowered specifications for lead, arsenic, and mercury and would have added a specification for cadmium in spirulina extract (see 21 CFR 73.530). Those specification changes are delayed indefinitely as of March 20, 2026 and are not in effect until the FDA takes further action.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-05732 — Listing of Color Additive Exempt From Certification; Beetroot Red; Delay of Effective Date
The FDA is hitting the pause button on the new rule that lets food makers use beetroot red as a color in most foods. This delay happens because some folks raised concerns, so the FDA needs more time to review before making it official. No money changes yet, but food companies and consumers will have to wait a bit longer for this colorful update.
Next: C1-2026-05113 — Amendments to HAVANA Act of 2021 Implementation Rules
The Department of State fixed a deadline typo in the HAVANA Act rules, giving people affected until May 15, 2026, instead of March 16, 2026, to take action. This change helps anyone involved get more time to meet the rules without rushing. No new money changes, just a clearer and fairer timeline!